Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502341 | 0.83 | ALDH1A1 (0.54) | KMT2AMEN1GAATSHRKDM4E | |
| SCHEMBL12866793 | 0.82 | GGPS1 (0.50) | GGPS1KMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL10224056 | 0.81 | GGPS1 (0.46) | GGPS1TSHR | |
| SCHEMBL9871229 | 0.80 | NOS1 (0.46) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL11764164 | 0.80 | GAA (0.50) | KMT2AMEN1GAA | |
| SCHEMBL12775663 | 0.80 | ALDH1A1 (0.48) | GGPS1KMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL10224068 | 0.80 | GGPS1 (0.48) | GGPS1GAATSHRKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL9870439 | 0.79 | NOS1 (0.47) | KMT2AMEN1GAAKDM4EALDH1A1 | |
| SCHEMBL10968800 | 0.79 | NOS1 (0.45) | KMT2AMEN1GAATSHRKDM4E | |
| SCHEMBL16841500 | 0.77 | GGPS1 (0.41) | GGPS1TSHRKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | GGPS1 1089/4885KMT2A 3066/4885MEN1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.